false
0000876378
0000876378
2022-03-10
2022-03-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_________________
FORM 8-K
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
March 10, 2022
Date of Report (date of earliest event reported)
_________________
Asensus Surgical, Inc.
(Exact name of Registrant as specified in its charter)
_________________
|
Delaware
(State or other jurisdiction of incorporation or organization)
|
|
0-19437
(Commission
File Number)
|
|
11-2962080
(I.R.S. Employer
Identification Number)
|
1 TW Alexander Drive, Suite 160
Durham, NC 27703
(Address of principal executive offices)
919-765-8400
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
_________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading symbol
|
|
Name of each exchange on which registered
|
|
Common Stock
$0.001 par value per share
|
|
ASXC
|
|
NYSE American
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 10, 2022, Jane Hsiao, Ph.D., a member of the Board of Directors of Asensus Surgical, Inc. (the “Company”) since 2005, informed the Company that she would not stand for re-election to the Board because of other commitments. Dr. Hsiao will leave the Board at the end of her current term, which expires at the 2022 Annual Meeting of Stockholders, to be held in June 2022.
Dr. Hsiao’s decision to resign as a director was not due to any disagreements with the Company on any matter relating to the Company’s operations, policies or practices.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ASENSUS SURGICAL, INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date: March 15, 2022
|
By:
|
/s/ Shameze Rampertab
|
|
|
|
|
Shameze Rampertab
|
|
|
|
|
Executive Vice President and Chief Financial Officer
|
|